PRAXIS PRECISION MEDICINES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $292.60 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $294.49, a 360.93% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $63.89, a 47.35% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $43.36, a 1359.93% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.97, a 83.15% decline year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $60.03, a 16.36% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $51.59, a 30.02% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $39.68, a 329.90% increase from fiscal 2022.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.23, a 76.09% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $292.60 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $294.49 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $60.03 10-K · filed 2026-02-19 | |||
| 2025-09-30 | $60.03 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $60.03 10-Q · filed 2025-08-04 | |||
| 2025-03-31 | $63.89 10-Q · filed 2025-05-02 | |||
| 2024-12-31 | $51.59 10-K · filed 2025-02-28 | |||
| 2024-09-30 | $51.43 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $43.65 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $43.36 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $39.68 10-K · filed 2024-03-05 | |||
| 2023-09-30 | $2.78 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $2.83 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $2.97 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $9.23 10-K · filed 2023-02-07 | |||
| 2022-09-30 | $9.29 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $9.38 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $17.63 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $38.60 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $43.26 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $44.78 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $52.60 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $9.10 10-K · filed 2021-03-17 | |||
| 2020-09-30 | $7.54 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |